ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Proadrenomedullin Predicts Severe Disease in Children With Suspected Community-acquired Pneumonia.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Systematic review and meta-analysis of the diagnostic value of four biomarkers in detecting neonatal sepsis in low- and middle-income countries.BMJ paediatrics open · 2023Pooled it
- The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections.PloS one · 2022Trial
- Adrenomedullin is a good marker of severity and prognosis in patients with bronchiolitis.European journal of pediatrics · 2026Observational
- Association of complete blood count parameters with adverse outcomes in acute pediatric pneumonia.Pediatric research · 2026Article
- Derivation and validation of the Pediatric Community-Acquired Pneumonia Severity (PedCAPS) score: A prospective cohort study.Journal of hospital medicine · 2026Article
- Prognostic role of mid-regional pro-adrenomedullin in predicting infection in pediatric cancer with febrile neutropenia.Clinical and experimental pediatrics · 2025Article
- Development and validation of an early diagnosis model for severe mycoplasma pneumonia in children based on interpretable machine learning.Respiratory research · 2025Article
- A Review on Risk Factors, Traditional Diagnostic Techniques, and Biomarkers for Pneumonia Prognostication and Management in Diabetic Patients.Diseases (Basel, Switzerland) · 2024Review
- Review
- Cost of Pediatric Pneumonia Episodes With or Without Chest Radiography.Hospital pediatrics · 2024Article
- Review of the Predictive Value of Biomarkers in Sepsis Mortality.Emergency medicine international · 2024Review
- Research progress of biomarkers in evaluating the severity and prognostic value of severe pneumonia in children.Frontiers in pediatrics · 2024Review
- Circulating markers of neutrophil activation and lung injury in pediatric pneumonia in low-resource settings.Pathogens and global health · 2023Article
- Kinetics and Role of Pancreatic Stone Protein and Midregional Proadrenomedullin as Predictors of Sepsis and Bacteremia in Children with Hematological Malignancies.Mediterranean journal of hematology and infectious diseases · 2023Article
- Clinical profile analysis and nomogram for predicting in-hospital mortality among elderly severe community-acquired pneumonia patients with comorbid cardiovascular disease: a retrospective cohort study.BMC pulmonary medicine · 2022Article
- Urinary Proadrenomedullin and Disease Severity in Children With Suspected Community-acquired Pneumonia.The Pediatric infectious disease journal · 2021Article
- Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.Laboratory medicine · 2021Observational
- Predictive and Prognostic Utility of the Serum Level of Resistin-Like Molecule Beta for Risk Stratification in Patients with Community-Acquired Pneumonia.Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundProadrenomedullin (proADM), a vasodilatory peptide with antimicrobial and anti-inflammatory properties, predicts severe outcomes in adults with community-acquired pneumonia (CAP) to a greater degree than C-reactive protein and procalcitonin. We evaluated the ability of proADM to predict disease severity across a range of clinical outcomes in children with suspected CAP.
methodsWe performed a prospective cohort study of children 3 months to 18 years with CAP in the emergency department. Disease severity was defined as mild (discharged home), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (eg, hospitalized with supplemental oxygen, broadening of antibiotics, complicated pneumonia), and severe (eg, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined using proportional odds logistic regression within the cohort with suspected CAP and in a subset with radiographic CAP.
resultsAmong 369 children, median proADM increased with disease severity (mild: median [IQR], 0.53 [0.43-0.73]; mild-moderate: 0.56 [0.45-0.71]; moderate-severe: 0.61 [0.47-0.77]; severe: 0.70 [0.55-1.04] nmol/L) (P = .002). ProADM was significantly associated with increased odds of developing severe outcomes (suspected CAP: OR, 1.68; 95% CI, 1.2-2.36; radiographic CAP: OR, 2.11; 95% CI, 1.36-3.38) adjusted for age, fever duration, antibiotic use, and pathogen. ProADM had an AUC of 0.64 (95% CI, .56-.72) in those with suspected CAP and an AUC of 0.77 (95% CI, .68-.87) in radiographic CAP.
conclusionsProADM was associated with severe disease and discriminated moderately well children who developed severe disease from those who did not, particularly in radiographic CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.